Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, London, UK.
Division of Surgery and Interventional Science, University College London, London, UK.
BJU Int. 2018 Jun;121(6):893-899. doi: 10.1111/bju.14159. Epub 2018 Mar 2.
To report on the contemporary UK experience of surgical management of renal oncocytomas.
Descriptive analysis of practice and postoperative outcomes of patients with a final histological diagnosis of oncocytoma included in The British Association of Urological Surgeons (BAUS) nephrectomy registry from 01/01/2013 to 31/12/2016. Short-term outcomes were assessed over a follow-up of 60 days.
Over 4 years, 32 130 renal surgical cases were recorded in the UK, of which 1202 were oncocytomas (3.7%). Most patients were male (756; 62.9%), the median (interquartile range [IQR]) age was 66.8 (13) years. The median (IQR; range) lesion size was 4.1 (3; 1-25) cm, 43.5% were ≤4 cm and 30.3% were 4-7 cm lesions. In all, 35 patients (2.9%) had preoperative renal tumour biopsy. Most patients had minimally invasive surgery, either radical nephrectomy (683 patients; 56.8%), partial nephrectomy (483; 40.2%) or other procedures (36; 3%). One in five patients (243 patients; 20.2%) had in-hospital complications: 48 were Clavien-Dindo classification grade ≥III (4% of the total cohort), including three deaths. Two additional deaths occurred within 60 days of surgery. The analysis is limited by the study's observational nature, not capturing lesions on surveillance or ablated after biopsy, possible underreporting, short follow-up, and lack of central histology review.
We report on the largest surgical series of renal oncocytomas. In the UK, the complication rate associated with surgical removal of a renal oncocytoma was not negligible. Centralisation of specialist services and increased utilisation of biopsy may inform management, reduce overtreatment, and change patient outcomes for this benign tumour.
报告英国目前在肾嗜酸细胞瘤的外科治疗方面的经验。
对 2013 年 1 月 1 日至 2016 年 12 月 31 日期间英国泌尿外科协会(BAUS)肾切除术登记处中最终组织学诊断为嗜酸细胞瘤的患者的手术治疗和术后结果进行描述性分析。术后 60 天内评估短期结果。
在 4 年期间,英国共记录了 32130 例肾脏手术病例,其中 1202 例为嗜酸细胞瘤(3.7%)。大多数患者为男性(756 例;62.9%),中位(四分位间距 [IQR])年龄为 66.8(13)岁。病变大小的中位数(IQR;范围)为 4.1(3;1-25)cm,43.5%为≤4cm,30.3%为 4-7cm 病变。共有 35 例(2.9%)患者术前进行了肾肿瘤活检。大多数患者接受了微创手术,包括根治性肾切除术(683 例;56.8%)、部分肾切除术(483 例;40.2%)或其他手术(36 例;3%)。五分之一的患者(243 例;20.2%)在院内发生并发症:48 例为 Clavien-Dindo 分级≥III 级(占总队列的 4%),包括 3 例死亡。另外 2 例死亡发生在术后 60 天内。该分析受到研究观察性质的限制,无法捕捉到监测或活检后消融的病变,可能存在漏报,随访时间短,以及缺乏中央病理审查。
我们报告了英国最大的肾嗜酸细胞瘤手术系列。在英国,手术切除肾嗜酸细胞瘤的并发症发生率不容忽视。集中专业服务和增加活检的使用可能会为这种良性肿瘤的治疗提供信息,减少过度治疗,并改变患者的结局。